Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 January 8, 2026 4:30 PM EST
Company Participants
Stephane Paquette – Vice President of Corporate Development
Krish Krishnan – Founder, Chairman, President & CEO
Suma Krishnan – Founder, President of R&D and Director
David Sweet
Trevor Parry
Conference Call Participants
Jorge Lascano
Ritu Baral – TD Cowen, Research Division
Jiale Song – Jefferies LLC, Research Division
Alec Stranahan – BofA Securities, Research Division
Gautam Chukka – Evercore ISI Institutional Equities, Research Division
Samantha Corwin – William Blair & Company L.L.C., Research Division
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Andrea Tan – Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Thank you for standing by, and welcome to Krystal Biotech’s Clinical Update Call for Cystic Fibrosis program, KB407. [Operator Instructions] As a reminder, today’s conference is being recorded.
I would now like to hand the conference over to your host, Stephane Paquette, Vice President of Corporate Development.
Stephane Paquette
Vice President of Corporate Development
Good afternoon, and thank you all for joining today’s call. Earlier today, we announced positive interim clinical results for Krystal Biotech’s cystic fibrosis program, KB407, including molecular confirmation of wild-type CFTR protein expression in patients’ lungs. The press release is available on our website at www.krystalbio.com. Both the press release and today’s presentation have also been filed as an 8-K with the SEC. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Trevor Parry, Vice President of Product Development; David Sweet, Director of Clinical Development; and Dr. Jorge Lascano, Professor of Medicine, Associate Director of the Adult Cystic Fibrosis Program and Director of the Cystic Fibrosis Therapeutics Development Center at the University of Florida.
This conference call will and our